Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Thermo Fisher Scientific director reports deferred stock unit grant
A Thermo Fisher Scientific Inc. (TMO) director reported receiving 64.72 phantom stock units on December 31, 2025 under the company’s Deferred Compensation Plan for Directors. These units are convertible into common stock on a 1-for-1 basis and were credited at a price of $579.45 per unit, based on the closing stock price at quarter end. Following this transaction, the director beneficially owns 2,638.67 derivative securities, held directly. Under the plan, directors’ retainers are deferred quarterly into common stock units, which are distributable as stock when director service ends for any reason or upon a change of control.
Thermo Fisher Scientific Inc. director transaction: Director Jennifer M. Johnson reported acquiring 53.93 phantom stock units tied to Thermo Fisher common stock on December 31, 2025. The units were credited at a price of $579.45 per unit under the company’s Deferred Compensation Plan for Directors.
Each phantom stock unit is convertible into one share of common stock and is distributable as stock after the director’s service ends or upon a change of control. Following this transaction, Johnson directly holds 595.29 phantom stock units. She is also President and Chief Executive Officer of Franklin Resources, Inc. and disclaims beneficial ownership of Thermo Fisher shares held in Franklin Templeton-managed client accounts.
Thermo Fisher Scientific director reports stock gift
Scott M. Sperling, a director of Thermo Fisher Scientific Inc., reported a transaction in the company’s common stock on December 10, 2025. The filing shows he disposed of 4,386 shares of common stock in a transaction coded "G," indicating a gift, at a reported price of $0 per share. Following this transaction, he beneficially owns 68,980 shares of Thermo Fisher Scientific common stock in direct ownership.
Thermo Fisher Scientific executive Michel Lagarde reported option exercises and a stock sale. On December 4, 2025, he exercised stock options for 18,637 shares of common stock at an exercise price of $105.17 per share and another 22,046 shares at an exercise price of $132.66 per share. On the same day, he sold 22,046 shares of Thermo Fisher Scientific common stock at a weighted average price of $563.56 per share, with individual sale prices ranging from $563.38 to $564.20.
After these transactions, Lagarde beneficially owned 84,116.909 shares of Thermo Fisher Scientific common stock in direct form. The options exercised had previously vested in scheduled installments in 2017, 2018, 2019 and 2020, and following the reported exercises, the specific option grants referenced now show 0 derivative securities remaining.
Thermo Fisher Scientific Inc. executive Michel Lagarde reported multiple stock option exercises and related stock sales. As Executive Vice President & COO, he filed a Form 4 for transactions dated December 2 and 3, 2025.
On December 2, Lagarde exercised options to acquire 36,000 shares of common stock at an exercise price of $105.17 per share, then sold 30,000 shares at a weighted average price of $581.92. On December 3, he exercised options for another 68,000 shares at $105.17, and sold 29,479 shares at a weighted average price of $583.33 plus 2,521 shares at a weighted average price of $584.11.
After these transactions, Lagarde directly held 65,479.909 shares of Thermo Fisher common stock and 18,637 stock options with a $105.17 exercise price expiring on July 20, 2026, which had vested in two equal installments on August 29, 2017 and 2020.
Thermo Fisher Scientific insider Michel Lagarde has filed a Form 144 indicating his intent to sell company stock. The notice covers 22,046 shares of common stock to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 12424320.59. The filing notes that 375708059 shares of common stock were outstanding.
Lagarde has also sold Thermo Fisher common shares in recent months. The notice lists sales of 4638 shares on 11/13/2025 for gross proceeds of 2756934.80, 30000 shares on 12/02/2025 for 17457612.00, and 32000 shares on 12/03/2025 for 18668515.20. By signing the notice, the seller represents that he is not aware of any material adverse, nonpublic information about the company’s current or prospective operations.
Thermo Fisher Scientific executive Thomas B. Shropshire, Jr., who serves as SVP and General Counsel, reported a change in his holdings of the company’s common stock. On 12/02/2025, he disposed of 337.476 shares of Thermo Fisher common stock in a transaction coded “F” at a price of $580.37 per share. After this transaction, he beneficially owned 5,079.524 shares, held directly.
Thermo Fisher Scientific executive Frederick M. Lowery, an Executive Vice President, reported option exercises and related stock sales in early December 2025. On December 1, 2025, he exercised 6,913 stock options at $253.99 per share and sold 6,913 shares of common stock at $597.68 per share. On December 2, 2025, he exercised an additional 6,912 options at $253.99 and sold 6,912 shares at $581.94 per share. After these transactions, he directly owned 14,367.3724 shares of Thermo Fisher common stock, with additional indirect holdings of 1,175.83 shares through a 401(k) plan and 5.036 shares through a limited liability company. The transactions were carried out under a Rule 10b5-1 trading plan adopted on August 28, 2025.
TMO insider Michel Lagarde filed a notice to sell 32,000 shares of common stock, with an aggregate market value of 18,668,514.70, through Fidelity Brokerage Services on the NYSE.
The table lists 375,708,059 shares of the issuer’s common stock as outstanding. Over the past three months, Lagarde previously sold 4,638 shares for gross proceeds of 2,756,934.80 and 30,000 shares for gross proceeds of 17,457,612.00.